NCT04296370 2020-08-10
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
Clinical Trials
1 trialsTreatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation × apatinib × Breast × Clear all